- Forex 40 +
BioNTech SE is a biotechnology company that specialises mainly in the development and manufacture of active immunotherapies. BioNTech has been working with Pfizer on a vaccine against the current coronavirus since January 2020. On November 9, it was announced with anticipation that the breakthrough was imminent.
According to initial data from the large clinical study, the vaccine candidate with the awkward name BNT162b2 from BioNTech and its partner Pfizer have achieved more than 90 percent effectiveness. As a result, the Mainz biotechnology company BioNTech was the first German company to test a vaccine on humans.
BioNTech is currently suffering from strong price fluctuations, which was to be expected because of the great expectations regarding the vaccine. Still, BioNTech and Pfizer expect to generate around $ 13 billion in profit next year.
But how will BioNTech develop further? Is it worth buying the share now? Is it safe to buy a share? This page deals with the basic data on the BioNTech share: price, ratings, outlook, analysis, forecasts, recommendations, history and where to buy the share online best.
You should pay attention to the following points when buying BioNTech shares:
To buy the BioNTech share, you first have to register with a broker of your choice. To buy a share, you always need a broker who buys the share on the market and then holds it in custody. It is advisable to pay particular attention to deposit protection. If the broker files for bankruptcy, the shares are retained thanks to deposit protection.
If choosing and evaluating stocks is too complicated, a social trading platform can also be a good solution. Here you follow an experienced trader and automatically copy the trader’s trading decisions.
Our broker recommendation at this point is Roinvesting – with state-guaranteed deposit protection of up to 20,000 euros and 0% commission when buying shares, Roinvesting is our test winner broker. To register with Roinvesting, click here.
If you have decided on a broker, you log in with your data and verify your email address. Then you can first try out the demo account, which has advantages. When one is ready to trade, one then proceeds to deposit.
After registering, you need to decide how much to invest in stocks. We generally recommend that you never invest more than 5% of your capital in a single share. So possible losses are manageable.
How much you want to invest in BioNTech shares, however, is entirely up to you. In this step, click on “Add money “.
Roinvesting offers various payment options with which you can deposit money into your customer account. The most popular payment options are PayPal, credit card or bank transfer. It should be noted that a bank transfer usually takes 2-3 working days for the credit to arrive on the customer account. However, if you want to have your money in your account faster, other payment methods are available.
Below is an overview of all the payment methods available at Roinvesting:
|Buy BioNTech shares with a credit card||✔️|
|Buy BioNTech shares with PayPal||✔️|
|Buy BioNTech Stock with Skrill||✔️|
|Buy BioNTech shares with bank transfer||✔️|
|Buy BioNTech Stock with Neteller||✔️|
|Buy BioNTech shares with UnionPay||✔️|
After the deposit, the money appears in your account under the menu item “Account”. First, find the BioNTech share using the search bar above and select it. Then click on the “Trade” button.
A small window will open to set the price and the number of shares you want to buy. You can also set stop-loss and take-profit, i.e. at which price the share should be sold again in the event of a profit or loss. The two fields are optional.
The Leverage field allows you to control whether you want to buy the real share (x1 leverage) or a CFD (x2 or more leverage).
The purchase is completed by clicking on “Place order,” and the share appears in your portfolio.
BioNTech SE is publicly traded biotechnology – companies that focus mainly on developing and producing active immunotherapies have specialised in treating cancer and other serious diseases.
The company was founded in 2008 in Mainz, Germany, founded and currently has 1,323 employees. In January 2019, BioNTech was converted from a stock corporation into a European stock corporation (“SE”). Before the company went public, it signed an agreement with the Bill & Melinda Gates Foundation (BMGF) to develop HIV and tuberculosis programs in September 2019. The initial listing on the US technology exchange Nasdaq then took place in October.
BioNTech has several collaboration agreements with pharmaceutical partners, including Pfizer. Together with Pfizer, BioNTech is working on the vaccine against COVID-19 and the development of mRNA-based vaccines to prevent influenza.
BioNTech went public for the first time in October 2019. However, the IPO in the USA turned out to be a tedious manoeuvre for the cancer research company BioNTech in Mainz and ultimately only succeeded with clear concessions to the new shareholders.
It has now been almost exactly a year since the biotechnology company BioNTech made its stock market debut. A lot has happened for the company since then. Here, in particular, has the global Corona pandemic as groundbreaking proven for the Mainz-based company. So many other companies had to accept major cuts, a great opportunity arose for the research company – which the biotech company knew how to use.
Stock prices shot up after research into the vaccine for COVID-19 was announced. Worldwide in the air. Virologists were enthusiastic. Investors have now also cast an eye on the German company.
Since the beginning of the year, the BioNTech share has so far gained a whopping 159.59%. The paper has now moved 486.33% off its issue price.
On October 10, 2019, the company dared to take the plunge into the trading floor. For this, they chose the US technology exchange Nasdaq despite their anchoring in Germany. The IPO itself was rather mixed: While the company had planned to place a total of 1 3.2 million shares with a range of 18 to 20 USD, ultimately only 10 million papers of 15 dollars each could be distributed to investors. This brought the biotech firm to a valuation of $ 3.4 billion. The company was able to collect a total of $ 149 million.
The first day of trading in the BioNTech share was also mixed. The daily range was between USD 13.01 and USD 16.70. The commercial paper was ultimately up to 14.24 USD and 13.7 percent below the Erstpreis, which stood at 16.50 USD. But interested investors can only dream of such prices today.
Because entering the race for a corona, vaccines gave the share a rapid rally.
As already mentioned, BioNTech has grown by 159.59% so far. The development of the COVID-19 vaccine caused the Group’s shares to skyrocket. The stock is currently trading at around $ 101.63. Quite a big jump if you assume the starting value of USD 13.82 in October 2019. So the prognoses are excellent.
The investor sentiment is a crucial sentiment indicator for the assessment of the stock. Recently, the BioNTech share was also the focus of discussions on social media. Above all and mostly positive opinions were published. In addition, the opinion market has been particularly concerned with the positive topics relating to BioNTech in the past few days. The BioNTech share is therefore rated “Buy” in this regard.
The GD200 of the value is 60.9 USD, whereby the stock price (101.63 USD) is +66.88 percent above this trend signal. Based on the past 50 days, the moving average is USD 80.04.
Sentiment and buzz: A long-term view of communication on the Internet also makes an essential contribution to the assessment of a share. The intensity of the discussion and changes in mood are considered. BioNTech showed interesting characteristics in this analysis. The intensity of the discussion changes significantly as increased activity can be seen. This results in a “buy” assessment.
BioNTech’s paper recently gained ground and rose in XETRA trading by 1.1 percent to EUR 88.79. As a result, the BioNTech share price rose to a daily high of EUR 89.89. At the start of XETRA trading, the share was quoted at EUR 89.30 (as of November 13, 2020).
Another buying argument is the share price target, which is currently USD 97.5.
The competition never sleeps. Especially in the corona pandemic, more and more pharmaceutical companies are working on developing a vaccine. Even if BioNTech and Pfizer have already applied to the FDA for approval, that doesn’t mean the vaccine will be a success. If contrary to all expectations, this should be a disappointment. The share may suffer a significant loss in value.
At the moment, however, analysts and experts are recommending a clear buy or at least a hold of the stock.
The Bloomberg business service lists 12 forecasts that focus on the BioNTech share. And they have different opinions about the forecast for the share: 6 experts forecast that the share will be bought, and five analysts recommend holding it. In addition, an expert advises on sales. It is also interesting to look at the analysts’ price target for the shares listed on the US technology exchange Nasdaq.
The average price forecast for BioNTech shares in one year is USD 88.80. This corresponds to a minus of over 20 percent compared to the current price. However, not all of these prognoses have yet reacted to BioNtech’s report of success. The latest recommendation comes from Daniel Wendorff from Commerzbank, who sees a target price of USD 119 for the share. On the other hand, JP Morgan’s Cory Kasimov has only assessed and set the price target at USD 90.
UBS analyst Navin Jacob estimates that Pfizer, BioNTech, and Chinese partner Fosun could generate sales of up to USD 50 billion with the vaccine over the next ten years.
Currently, Pfizer and BioNTech are at the forefront of developing the corona vaccine. However, other pharmaceutical companies are also involved. These stocks could be of interest to investors during the pandemic:
We compare the fees of the largest brokers with the following example:
With these assumptions, we now compare the fees of Libertex, Roinvesting & Plus500 :
|Deposit||for free||for free||for free|
|Purchase fees||€ 2.20||0%||3.08%|
|Holding fees||for free||for free||0.05%|
|Sales charges||€ 2.20||0%||3.08%|
|Payout||for free||5 USD||1.9%|
|Total fees||€ 4.40||€ 4.22||€ 92.32|
BioNTech and Pfizer are about to approve a COVID-19 vaccine. A successful launch could. Therefore, another course buoyancy bestows – the share price of BioNTech SE has climbed earlier this week to a new all-time high – a definite buy signal!
The company is leading the development of a corona vaccine. However, since the company only went public last year, there is still no very long chart history. But this is long enough to see a clear, positive upward trend.
As with Pfizer shares, investors are very positive. However, it is generally advised to first wait for the vaccine study results. If the announced results come true, BioNTech shares could reach an all-time high. The company is currently doing very well, and the upward trend seems almost unstoppable.
According to experts and analysts, most of the signs point to Buy. The share is currently also showing a clear upward trend. The paper has now moved 486.33% off its issue price. Should the vaccine against COVID-19 actually be a success, BioNTech could be very successful.
BioNTech has been listed on the largest electronic exchange, the American Nasdaq, since its IPO in October 2019.
We generally recommend not investing more than 5% of the capital in a share. However, how much you invest in the stock is ultimately up to the investor. There is always a risk.
A trusted broker will contact you today.